Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-VEGF (CHARTRES)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 71
- 试验地点
- 1
- 主要终点
- Central Retinal Thickness (Change from screening)
研究概览
简要总结
The purpose of this study is to identify Diabetic Macular Edema (DME) characteristics in eyes that show different response to treatment with anti-VEGF (vascular endothelial growth factor) injections of Lucentis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with 40 years of age or older.
- •Type 2 Diabetes Mellitus.
- •Glycosylated hemoglobin (HbA1C) ≤ 12% at screening visit.
- •Presence of clinically significant DME involving the center (fovea) diagnosed in at least one eye that is eligible for anti-VEGF treatment in the opinion of the investigator. If both eyes are eligible, the one with the worse visual acuity, as assessed at screening visit, will be selected as the study eye.
- •Visual impairment due to DME with BCVA ≥ 39 letters and ≤ 73 letters (≥ 20/160 and ≤ 20/40).
- •Central subfield thickness ≥ 300µm.
排除标准
- •Presence of any other ocular disease than DME in the study eye that may confound study results, such as Proliferative Retinopathy.
- •Previous treatment with vitrectomy or intravitreous injections of triancinolone or anti-VEGF drugs in the study eye.
- •Any previous laser photocoagulation (panretinal or focal) in the study eye within 6 months prior to inclusion in this study.
- •Active intraocular inflammation (grade trace or above) in either eye at screening visit.
- •Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye at screening visit.
- •Important refractive errors (myopia > 6D) or opacification of clear media that interferes with images evaluation.
- •Patients with renal failure or other systemic conditions which, in the opinion of the investigator, would preclude schedule study visits, completion of the study or a safe administration of study medication.
- •Other criteria that in the opinion of the investigator should condition the evaluation purposed.
结局指标
主要结局
Central Retinal Thickness (Change from screening)
时间窗: Change from Screening at 3 Months
Measured by Spectral Domain Optical Coherence Tomography (OCT)
Presence of OCT diffuse macular edema (without cyst formation) (change from screening)
时间窗: Change from Screening at 3 Months
Presence of neurosensorial retinal detachment. (change from screening)
时间窗: Change from Screening at 3 Months
Degree of integrity of the photoreceptors in the inner/outer segments layer in the 1 mm centered in the fovea (change from screening)
时间窗: Change from Screening at 3 Months
Presence and extension of capillary occlusion (change from screening)
时间窗: Change from Screening at 3 Months
Area of macular leakage (intraretinal fluid volume and retinal thickness) (change frmo screening)
时间窗: Change from Screening at 3 Months
次要结局
- Best Corrected Visual Acuity (BCVA) (Change from screening)(Change from Screening at 3 Months)
- Central Retinal Thickness (change from screening)(Change from Screening at 6 Months)
- Presence (and location) of cysts in the retinal layers (change from screening)(Change from Screening at 6 Months)
- Presence of OCT diffuse macular edema (without cyst formation) (change from screening)(Change from Screening at 6 months)
- Presence of neurosensorial retinal detachment. (change from screening)(Change from Screening at 6 Months)
- Degree of integrity of the photoreceptors in the inner/outer segments layer in the 1 mm centered in the fovea (change from screening)(Change from Screening at 6 months)
- Presence and extension of capillary occlusion (change from screening)(Change from Screening at 6 Months)
- Area of macular leakage (intraretinal fluid volume and retinal thickness) (change from screening)(Change from Screening at 6 Months)
- Best Corrected Visual Acuity (change from screening)(Change from Screening at 6 Months)